Abstract:Background: Chronic obstructive pulmonary disease (COPD) is characterized by chronic inflammation throughout the airways, parenchyma, and pulmonary vasculature. The inflammation causes repeated cycles of injury and repair in the airway wall— inflammatory cells release a variety of chemicals and lead to cellular damage. The inflammation process also contributes to the loss of elastic recoil pressure in the lung, thereby reducing the driving pressure for expiratory flow through narrowed and poorly supported airways, in which airflow resistance is significantly increased. Expiratory flow limitation is the pathophysiological hallmark of COPD. Exacerbations of COPD contribute considerably to morbidity and mortality, and impose a burden on the health care system. They are a leading cause of emergency room visits and hospitalizations, particularly in the winter. In Canada, the reported average cost for treating a moderate exacerbation is $641; for a major exacerbation, the cost is $10,086. Objective: The objective of this study was to evaluate the cost-effectiveness and budget impact of the following interventions in moderate to very severe COPD, investigated in the Medical Advisory Secretariat Chronic Obstructive Pulmonary Disease Mega-Analysis Series: smoking cessation programs in moderate COPD in an outpatient setting:– intensive counselling (IC) versus usual care (UC)– nicotine replacement therapy (NRT) versus UC– IC + NRT versus placebo– bupropion versus placebomultidisciplinary care (MDC) teams versus UC in moderate to severe COPD in an outpatient settingpulmonary rehabilitation (PR) versus UC following acute exacerbations in moderate to severe COPDlong-term oxygen therapy (LTOT) versus UC in severe hypoxemia in COPD in an outpatient settingventilation:– noninvasive positive pressure ventilation (NPPV) + usual medical care versus usual medical care in acute respiratory failure due to an acute exacerbation in severe COPD in an inpatient setting– weaning with NPPV versus weaning with invasive mechanical ventilation in acute respiratory failure due to an acute exacerbation in very severe COPD in an inpatient setting Methods: A cost-utility analysis was conducted using a Markov probabilistic model. The model consists of different health states based on the Global Initiative for Chronic Obstructive Lung Disease COPD severity classification. Patients were assigned different costs and utilities depending on their severity health state during each model cycle. In addition to moving between health states, patients were at risk of acute exacerbations of COPD in each model cycle. During each cycle, patients could have no acute exacerbation, a minor acute exacerbation, or a major exacerbation. For the purposes of the model, a major exacerbation was defined as one that required hospitalization. Patients were assigned different costs and utilities in each model cycle, depending on whether they experienced an exacerbation, and its severity. Starting cohorts reflected the various patient populations from the trials analyzed. Incremental cost-effectiveness ratios (ICERs)—that is, costs per quality-adjusted life-year (QALY)—were estimated for each intervention using clinical parameters and summary estimates of relative risks of (re)hospitalization, as well as mortality and abstinence rates, from the COPD mega-analysis evidence-based analyses. A budget impact analysis was also conducted to project incremental costs already being incurred or resources already in use in Ontario. Using provincial data, medical literature, and expert opinion, health system impacts were calculated for the strategies investigated. All costs are reported in Canadian dollars. Results: All smoking cessation programs were dominant (i.e., less expensive and more effective overall). Assuming a base case cost of $1,041 and $1,527 per patient for MDC and PR, the ICER was calculated to be $14,123 per QALY and $17,938 per QALY, respectively. When the costs of MDC and PR were varied in a 1-way sensitivity analysis to reflect variation in resource utilization reported in the literature, the ICER increased to $55,322 per QALY and $56,270 per QALY, respectively. Assuming a base case cost of $2,261 per year per patient for LTOT as reported by data from the Ontario provincial program, the ICER was calculated to be $38,993 per QALY. Ventilation strategies were dominant (i.e., cheaper and more effective), as reflected by the clinical evidence of significant in-hospital days avoided in the study group. Ontario currently pays for IC through physician billing (translating to a current burden of $8 million) and bupropion through the Ontario Drug Benefit program (translating to a current burden of almost $2 million). The burden of NRT was projected to be $10 million, with future expenditures of up to $1 million in Years 1 to 3 for incident cases. Ontario currently pays for some chronic disease management programs. Based on the most recent Family Health Team data, the costs of MDC programs to manage COPD were estimated at $85 million in fiscal year 2010, with projected future expenditures of up to $51 million for incident cases, assuming the base case cost of the program. However, this estimate does not accurately reflect the current costs to the province because of lack of report by Family Health Teams, lack of capture of programs outside this model of care by any data set in the province, and because the resource utilization and frequency of visits/follow-up phone calls were based on the findings in the literature rather than the actual Family Health Team COPD management programs in place in Ontario. Therefore, MDC resources being utilized in the province are unknown and difficult to measure. Data on COPD-related hospitalizations were pulled from Ontario administrative data sets and based on consultation with experts. Half of hospitalized patients will access PR resources at least once, and half of these will repeat the therapy, translating to a potential burden of $17 million to $32 million, depending on the cost of the program. These resources are currently being absorbed, but since utilization is not being captured by any data set in the province, it is difficult to quantify and estimate. Provincial programs may be under-resourced, and patients may not be accessing these services effectively. Data from the LTOT provincial program (based on fiscal year 2006 information) suggested that the burden was $65 million, with potential expenditures of up to $0.2 million in Years 1 to 3 for incident cases. From the clinical evidence on ventilation (i.e., reduction in length of stay in hospital), there were potential cost savings to the hospitals of $42 million and $12 million for NPPV and weaning with NPPV, respectively, if the study intervention were adopted. Future cost savings were projected to be up to $4 million and $1 million, respectively, for incident cases. Conclusions: Currently, costs for most of these interventions are being absorbed by provider services, the Ontario Drug Benefit Program, the Assistive Devices Program, and the hospital global budget. The most cost-effective intervention for COPD will depend on decision-makers’ willingness to pay. Lack of provincial data sets capturing resource utilization for the various interventions poses a challenge for estimating current burden and future expenditures.

Abstract:Chronic obstructive pulmonary disease (COPD) remains a major public health problem. The Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease was first published by the Global Initiative for Chronic Obstructive Lung Disease (GOLD) in 2001. A major revision was undertaken in 2011 and an update to it was published in February this year.1Global Initiative for Chronic Obstructive Lung Disease (GOLD)Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: revised 2011.http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdfGoogle Scholar The Chinese Society of Respiratory Disease recently released new Chinese COPD guidelines,2Chinese Society of Respiratory DiseaseThe guideline for the diagnosis and treatment of chronic obstructive pulmonary disease.Zhonghua Jie He He Hu Xi Za Zhi. 2013; 36: 255-264Google Scholar which recommend that the same strategy is used in China. However, whether this new system proves to be an improvement on the old system and whether it is applicable in China remains controversial and needs further research. Many differences exist between China and the developed countries that most of the GOLD committee members come from. 4·3 million people in China have COPD, and the disease prevalence is significantly higher in rural (8·8%) than in urban areas (7·8%; p=0·007).3Zhong NS Wang C Yao WZ et al.Prevalence of chronic obstructive pulmonary disease in China.Am J Respir Crit Care Med. 2007; 176: 753-760Crossref PubMed Scopus (625) Google Scholar 36·4% of practising Chinese doctors work at basic medical facilities (including community health service centres, small rural hospitals, village health rooms, clinics, and nurses' stations). The educational level of these doctors is worrying. Of licensed doctors, only 8·3% have a post-graduate degree and 43·6% have a bachelor's degree. Thus, nearly half of all doctors in China have quite a low level of education, and the situation for licensed assistant doctors is even worse.4National Health and Family Planning CommissionChina Health Statistical Yearbook.http://www.moh.gov.cn/htmlfiles/zwgkzt/ptjnj/year2011/index2011.htmlDate: 2011Google Scholar Use of the GOLD criteria in China encounters several problems, as outlined below. The assessment of symptoms in patients with COPD is based on either the modified Medical Research Council (mMRC) or the COPD Assessment Test score. In GOLD 2013, the Clinical COPD Questionnaire is also introduced. In clinical practice in China, 40–80 patients are seen per doctor per day, without enough nurses or physician assistants to help. Therefore, whichever is the easiest method to assess symptoms is judged to be the best. In one of our studies5Zhou QT Mei JJ He B et al.Chronic obstructive pulmonary disease assessment test score correlated with dyspnea score in a large sample of Chinese patients.Chin Med J. 2013; 126: 11-15PubMed Google Scholar we enrolled 6437 patients in 329 hospitals across China and found that the COPD Assessment Test score was moderately correlated with mMRC dyspnoea grade (r=0·579, p<0·001). The most practical approach is for physicians to ask only one question—"do you feel breathless when walking?"—and quickly obtain the mMRC score. Therefore, use of only mMRC might be suitable for Chinese clinical practice. Spirometry is needed to diagnose COPD in the new GOLD 2011 criteria and spirometric tests are always important in the assessment of the disease. However, spirometry is not correctly or widely used in China. He and colleagues6He QY Zhao Q Ye RJ et al.Preliminary investigation on lung function test in diagnosis of chronic obstructive pulmonary disease in some provinces and cities of China.Zhonghua Jie He He Hu Xi Za Zhi. 2003; 26: 39-40Google Scholar reported that only 50% of patients with COPD had ever had spirometry tests in tertiary hospitals, and only 18% had in primary or secondary hospitals. In our epidemiological survey in a rural area of Beijing,7Shen N Yao WZ Zhu H Patient's perspective of chronic obstructive pulmonary disease in Yanqing county of Beijing.Zhonghua Jie He He Hu Xi Za Zhi. 2008; 31: 206-208PubMed Google Scholar none of the 148 patients with COPD had ever undergone spirometry. This situation is due to inadequate physician knowledge about the disease and a scarcity of equipment in lower-level hospitals. A solution could be to use different methods in different hospitals. Although the GOLD criteria are suitable for use in tertiary hospitals, other methods such as peak expiratory flow rate could be used instead in primary or secondary hospitals, since their sensitivity and specificity are quite good.8Jackson H Hubbard R Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey.BMJ. 2003; 327: 653-654Crossref PubMed Scopus (77) Google Scholar The risk of exacerbation can be assessed in several ways: symptoms, use of medication, and admission to hospital. However, several questions remain to be answered in Chinese clinical practice. For example, the time of an acute exacerbation is often inaccurate because many patients have a poor understanding of the disease,7Shen N Yao WZ Zhu H Patient's perspective of chronic obstructive pulmonary disease in Yanqing county of Beijing.Zhonghua Jie He He Hu Xi Za Zhi. 2008; 31: 206-208PubMed Google Scholar, 9Lou P Zhu Y Chen P et al.Vulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: a cross-sectional study.BMC Public Health. 2012; 12: 287-293Crossref PubMed Scopus (43) Google Scholar and they might be unwilling or unable to write a COPD diary. Changes in medication, such as use of short-acting β2-agonists, antibiotics, or oral corticosteroids, might be strongly affected by the knowledge of the physicians and the financial situation of the patients. In our study,7Shen N Yao WZ Zhu H Patient's perspective of chronic obstructive pulmonary disease in Yanqing county of Beijing.Zhonghua Jie He He Hu Xi Za Zhi. 2008; 31: 206-208PubMed Google Scholar none of the stable patients with COPD took inhalers regularly or as needed. During acute exacerbations, only 6·8% took theophylline and 6·8% antibiotics. Another Chinese study9Lou P Zhu Y Chen P et al.Vulnerability, beliefs, treatments and economic burden of chronic obstructive pulmonary disease in rural areas in China: a cross-sectional study.BMC Public Health. 2012; 12: 287-293Crossref PubMed Scopus (43) Google Scholar reported similar results. However, in China, patients can obtain antibiotics easily. Many people keep antibiotics in reserve at home and they tend to show a preference for these drugs. Thus, use of antibiotics does not always indicate an acute exacerbation. Finally, the indication of hospital admission varies in different hospitals, and is affected by socioeconomic factors, the health system, and policy. Inhaled corticosteroids, long-acting β-agonists, and long-acting muscarinic agonists are all expensive drugs and many patients in China cannot afford them. An alternative pharmacological treatment for COPD, phosphodiesterase-4 inhibitor, is awaiting approval by the China State Food and Drug Administration. In our 2008 study,7Shen N Yao WZ Zhu H Patient's perspective of chronic obstructive pulmonary disease in Yanqing county of Beijing.Zhonghua Jie He He Hu Xi Za Zhi. 2008; 31: 206-208PubMed Google Scholar only 4·1% of stable patients with COPD took theophylline, and did so irregularly. Despite the fact that this study was done 5 years ago, the present situation is still not optimistic. Although most people living in rural areas have joined the New Rural Co-operative Medical System of China, the proportion of reimbursement is quite low. For example, the reimbursement for admission to hospital is only 30% for tertiary hospitals and 40% for secondary hospitals in many regions. Thus, only patients with a high standard of living and a high level of education can follow the guidelines. We should have our own guidelines with patient stratification, and assessment of theophylline, carbocysteine, and other alternative drugs to make them more applicable in China. A basic version of treatment for COPD could be introduced (and would exist alongside the standard treatments), which would enable more general doctors to use available methods of diagnosis and treatment, and give patients in rural or remote areas the opportunity to have affordable and appropriate treatment. In conclusion, the GOLD 2011 criteria and the new COPD guidelines in China enable a better understanding of the effects of the disease. However, the applicability of the GOLD criteria in China is still questionable. Perhaps future guidelines will expand these concepts by taking into account the characteristics of developing countries, and will be modified according to local clinical practice in different countries. We declare that we have no conflicts of interest.

Effectiveness of Hospital Pharmacist Interventions for COPD Patients: A Systematic Literature Review and Logic Model

Exploration of quantitative-effectiveness association between acupuncture temporal parameters and stable chronic obstructive pulmonary disease: A systematic review and dose-response meta-analysis of randomized controlled trials

Effect of pharmacist-led interventions on medication adherence and inhalation technique in adult patients with asthma or COPD: A systematic review and meta-analysis

Educational interventions for health professionals managing chronic obstructive pulmonary disease in primary care.

Cost-effectiveness of interventions for chronic obstructive pulmonary disease (COPD) using an Ontario policy model

Effects of Early Pulmonary Rehabilitation on Hospitalized Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis

The Impact of the Pay-for-Performance Program on the Outcome of COPD Patients in Taiwan After One Year

Real-World COPD Management Over 3 Years at the Community Health Service Center of Shanghai During the COVID-19 Pandemic in China

Cost-Effectiveness of Humidified High-Flow Therapy (HHFT) for COPD Patients on Long-Term Oxygen Therapy

A Systematic Literature Review of the Humanistic Burden of COPD

Effectiveness of Telemedicine Intervention for Chronic Obstructive Pulmonary Disease in China: A Systematic Review and Meta-Analysis.

Effectiveness of clinical pharmacist intervention on medication adherence in patients with chronic obstructive pulmonary disease - A randomized controlled study

Application of the Clinical Outcomes, Healthcare Resource Utilization, and Related Costs Model in Chronic Obstructive Pulmonary Disease Patients

Exploring Factors Contributing to Chronic Obstructive Pulmonary Disease (COPD) Guideline Non-Adherence and Potential Solutions in the Emergency Department: Interdisciplinary Staff Perspective

Economic Burden of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Literature Review

Mapping the Common Barriers to Optimal COPD Care in High and Middle-Income Countries: Qualitative Perspectives from Clinicians

Cost-effectiveness of home care compared to hospital care in patients with chronic obstructive pulmonary disease (COPD): a systematic review

Management of COPD and Comorbidities in COPD patients by Dispensing Pharmaceutical Care following Global Initiative for chronic Obstructive Lung Disease-Guidelines (GOLD guidelines 2020): A study protocol for a Prospective Randomized Clinical Trial

Home‐based management on hospital re‐admission rates in COPD patients: A systematic review

Clinical decision support systems for chronic obstructive pulmonary disease (COPD) in hospitals: A systematic review

Is the New GOLD Classification Applicable in China?